Atracurium besylate

Research use only, not for human use.

Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

Atracurium Besilate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent.(In Vitro):Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells.Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs.Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells.(In Vivo):Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice.Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats.

Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells.Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs.Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells. Cell Proliferation Assay Cell Line:glioblastoma stem (GSC) cells Concentration:3, 10, 20 μM Incubation Time:72 h Result:Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively.

Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice.Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats. Animal Model:5-12 weeks, 15-20 g male mice Dosage:1, 5, 10, 20, 50 mg/kg Administration:I.v.Result:Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium.Animal Model:290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i.v.)Dosage:4.8 mg/kg Administration:I.v.Result:Induced neuromuscular blockade in Corynebacteriumparvum-injected rats.

Atracurium Besylate | Atracurium Dibesylate

Others

Other Targets

nAChR

Neurological Disease

——

64228-81-5

1243.49

C65H82N2O18S2

>98% (HPLC)

DMSO : 50 mg/mL 40.21 mM

[O-]S(=O)(=O)c1ccccc1.COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.[O-]S(=O)(=O)c1ccccc1

benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate

(-20℃)

With Ice Pack

≥ 2 years